Barbara Ann Karmanos Cancer Institute Clinical Trials
Sponsors / Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov lists 162 trials for which Barbara Ann Karmanos Cancer Institute is named as lead sponsor. The portfolio currently includes 16 recruiting studies, 6 active non-recruiting studies, and 110 completed studies. 23 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include slow or insufficient recruitment, funding constraints. Cumulative planned enrollment across all listed trials is 10,625 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.
162
Total Trials
16
Recruiting
6
Other Active
110
Completed
23
Terminated / Withdrawn
10,625
Total Enrollment
Termination reasons: Recruitment39% · Other26% · Funding22% · Safety9% · Regulatory4%
Recent Terminations
- Pancreas Adenocarcinoma"The pharmaceutical funder pulled funding and no longer plans to develop the drug further."
- Glioblastoma"slow accrual"
- Immunotherapy"Low accrual"
- Metastatic Castration-resistant Prostate Cancer"The study was stopped due to insurmountable enrollment challenges affecting trial accrual, resulting from the rapidly evolving treatment options for advanced prostate cancer."
- Castration Levels of Testosterone"The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA events."
- Light Chain Deposition Disease"FDA placed the study on a clinical hold, due to the concerns by the FDA and Health Canada, Celgene decided to permanently close the study."
- Hodgkin's Lymphoma"Study terminated due to slow accrual."
- Hodgkin's Lymphoma"Low accrual. No Analyses were performed"
- Childhood Choroid Plexus Tumor
- Recurrent Non-small Cell Lung Cancer"Slow accrual."
Active Trials (6 total)
- NCT07218432
- Multiple Myeloma PHASE1NCT03091257
- NCT07436078
- Hodgkin Lymphoma PHASE1/PHASE2NCT03033914
- Breast Cancer PHASE1NCT05556473
- NCT07118202
- Multiple Myeloma PHASE3NCT01208662
- NCT07130903
- NCT03750981
- NCT06576115
- Advanced Solid Tumor PHASE1NCT07098299
- Diffuse Large B-Cell Lymphoma PHASE1/PHASE2NCT03147885
- NCT04479267
- NCT07095114
- Cancer NANCT06908629
- NCT01888198
- NCT02178163
- NCT00935090
- NCT07042191
- Amyloidosis NANCT05738005